Syngene Shares Surge 17% Despite 19% Drop in Q4 Net Profit
Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?
The Economic Times
Image: The Economic Times
Syngene International, a contract research and manufacturing organization based in India, saw its shares rise nearly 17% despite reporting a 19% year-on-year decline in net profit for Q4 FY26. Key management changes and a strong sequential profit surge contributed to investor optimism, with revenue also showing growth.
- 01Syngene's Q4 net profit dropped 19% year-on-year but rose significantly from the previous quarter.
- 02Revenue from operations grew 2% year-on-year and over 13% sequentially.
- 03Kiran Mazumdar-Shaw transitioned to Executive Chairman, emphasizing growth and new business lines.
- 04Siddharth Mittal will succeed Peter Bains as Managing Director and CEO starting July 1, 2026.
- 05Macquarie maintains an 'Outperform' rating with a target price suggesting a 93% upside potential.
Advertisement
In-Article Ad
Shares of Syngene International, a contract research and manufacturing organization in India, surged nearly 17% on Thursday, despite reporting a 19% year-on-year decline in net profit for the fourth quarter of the financial year 2026. The company reported a net profit of ₹148 crore for Q4 FY26, a significant increase from ₹15 crore in the previous quarter. Revenue from operations grew nearly 2% to ₹1,036.5 crore, with a 13% sequential increase from the previous quarter. Key management changes, including Kiran Mazumdar-Shaw's transition to Executive Chairman, have been highlighted as pivotal for the company's growth trajectory. The company is focusing on expanding its service offerings and investing in AI and digital capabilities to enhance productivity. Notably, Siddharth Mittal will take over as Managing Director and CEO from July 1, 2026. Macquarie has maintained an 'Outperform' rating on Syngene shares, projecting a target price of ₹835, indicating a potential upside of over 93% from the current trading price of ₹505.60.
Advertisement
In-Article Ad
The share price increase may boost investor confidence and attract further investment in Syngene, potentially enhancing its market position in the life sciences sector.
Advertisement
In-Article Ad
Reader Poll
Do you think Syngene's management changes will positively impact its future growth?
Connecting to poll...
Read the original article
Visit the source for the complete story.